BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity

Readout sets up ‘first-in-class’ therapy for Phase IIb study in increasingly competitive inflammatory disease

An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers

Emerging Company Profile: Ranok has raised $40M to test whether alternative to PROTACs could have safety, dosing advantages

bluebird revealed late Wednesday in its 4Q20 earnings that FDA placed a clinical hold on its trials of LentiGlobin due to suspected unexpected serious adverse reactions in the Phase I/II HGB-206

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and

BioCentury’s roundup of preclinical news

Measuring PK/PD in real time by selectively targeting protein networks